[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-170813-105":53,"doc-detail-170813-en":127},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":120,"head_meta":122,"extra_data":124,"updated_unix":126},105,"en","template-letter-of-appeal-for-atopic-dermatitis-sample","TEMPLATE LETTER OF APPEAL FOR ATOPIC DERMATITIS - Sample","","Template letter for appealing a prior authorization denial for OPZELURA® (ruxolitinib) cream 1.5% in patients with mild to moderate atopic dermatitis. The letter instructs the prescriber to address the specific denial reason, provide customized bracketed patient and case details, and include clinical rationale supporting medical appropriateness. It also prompts documentation of prior treatment failures, step-through requirement status when applicable, and body surface area considerations. Includes relevant indication and safety information.",{"@graph":63,"@context":119},[64,80,102],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":41,"@type":70,"position":76},"https://docshare.wps.com/template/letters/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/template-letter-of-appeal-for-atopic-dermatitis-sample/170813/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/template-letter-of-appeal-for-atopic-dermatitis-sample/170813.png","ImageObject",442,249,{"name":88,"@type":89},"Gelato","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/vnd.openxmlformats-officedocument.wordprocessingml.document","2026-10-19","2026-09-01",true,{"@type":98,"interactionType":99,"userInteractionCount":101},"InteractionCounter",{"@type":100},"ViewAction",9,{"@type":103,"mainEntity":104},"FAQPage",[105,111,115],{"name":106,"@type":107,"acceptedAnswer":108},"What information must be included to appeal a prior authorization denial?","Question",{"text":109,"@type":110},"The denial reason from the prior authorization denial letter must be directly addressed, along with patient details, diagnosis codes, case/request ID, and a clinical rationale supporting medical appropriateness for OPZELURA.","Answer",{"name":112,"@type":107,"acceptedAnswer":113},"How should the prescriber address step-through requirements in the appeal?",{"text":114,"@type":110},"If applicable, the prescriber should confirm the patient met the plan’s step-through requirements or explain why step-through drugs are ineffective, contraindicated, or not tolerated. The template notes some plans may not require topical corticosteroids in sensitive areas.",{"name":116,"@type":107,"acceptedAnswer":117},"What safety concerns are highlighted for OPZELURA in this template?",{"text":118,"@type":110},"Patients may be at risk for serious infections, including active tuberculosis and invasive fungal infections. The template advises avoiding use in patients with active serious infection, stopping treatment if serious infection develops, and monitoring for infection signs.","https://schema.org",{"og:url":78,"og:type":121,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":123,"canonical":78},"index,follow",{"doc_id":125,"site_id":56},170813,1788276031,{"code":4,"msg":5,"data":128},{"doc_id":125,"user_id":129,"nickname":88,"user_avatar":130,"doc_module":9,"category_id":40,"category_name":41,"doc_title":59,"doc_description":61,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":101,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":136,"language":137,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":138,"faqs":139,"seo_title":140,"seo_description":61,"update_tm":126,"read_time":73},19241457091524,"https://us-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","TEMPLATE LETTER OF APPEAL FOR ATOPIC DERMATITIS\nWhen a Prior Authorization is denied, it can be appealed following the health plan’s process for appeals. Please refer to the Prior Authorization denial letter to obtain the denial reason and information on the plan’s appeal submission process. \u000bThe denial reason should be directly addressed in the appeal letter.\nThe prescriber should refer to the Full Prescribing Information for OPZELURA® (ruxolitinib) cream 1.5% when determining whether the product is medically appropriate for a patient.\nThe following template letter is only intended as a SAMPLE Letter of Appeal for mild to moderate atopic dermatitis and outlines the information a payer may need when \u000breviewing an appeal.\nThe prescriber is responsible for customizing all bracketed information in magenta with the appropriate information.\nPlease see \u0013 HYPERLINK \"https://www.opzelura.com/prescribing-information.pdf\" \u0014Full Prescribing Information\u0015, including Boxed Warning,\nand \u0013 HYPERLINK \"https://www.opzelura.com/medication-guide.pdf\" \u0014Medication Guide\u0015 for OPZELURA.\n\u000f\nTEMPLATE LETTER OF APPEAL FOR ATOPIC DERMATITIS\n\u003C\u003CPhysician’s Letterhead>>\n\u003C\u003CDate>>\n\u003C\u003CAttention: Payer Contact Name/Payer Department>>\n\u003C\u003CInsert Name of Health Insurance Company>>\n\u003C\u003CInsert Health Plan’s Address for Appeal Submissions>>\n\u003C\u003CCity, State, ZIP Code>>\nRE: Request for Appeal for OPZELURA® (ruxolitinib) cream 1.5%\nPatient: \u003C\u003CPatient Name>>\nDate of Birth: \u003C\u003CDate of Birth>>\nDiagnosis: Mild to Moderate Atopic Dermatitis \u003C\u003CICD-10-CM>>\nGroup/Policy Number: \u003C\u003CNumber>>\nPolicyholder: \u003C\u003CPolicyholder Name>>\nCase or Request ID: \u003C\u003CCase/request ID/reference # listed on PA denial letter>>\nTo Whom It May Concern:\nOn behalf of my patient, this letter is to appeal the denial of coverage for OPZELURA for the treatment of mild to moderate atopic dermatitis. The denial reason stated was \u003C\u003Cinsert coverage denial reason>>.\n\u003C\u003CPatient Name>> is \u003C\u003CAge>> years old and has been diagnosed with mild to moderate atopic dermatitis, \u003C\u003CICD-10 code>>. After reviewing the denial letter, I maintain that OPZELURA is the appropriate therapy for my patient. \u003C\u003CPatient Name>> has been in my care since \u003C\u003Cmonth, year>>. Listed below is a summary of the patient’s medical history and relevant clinical information that supports the use of OPZELURA for this patient.\n\u003C\u003CInclude your clinical rationale and reasons for prescribing the product, highlighting factors leading you to recommend the use of this product, and be sure to address the Prior Authorization (PA) denial reason.>>\n\u003C\u003CIf applicable, provide information confirming the patient has met the plan’s step-through requirements and/or why the patient is unable to take these drugs due to ineffectiveness, contraindications, and/or intolerance. Note: Many plans do not require the use of a topical corticosteroid (TCS) if the drug is to be used in sensitive areas. Examples of step-through drugs include TCSs, such as clobetasone or triamcinolone, or a topical calcineurin inhibitor (TCI), such as tacrolimus or pimecrolimus.>>\nMy patient has tried and failed other therapies for mild to moderate atopic dermatitis, including:\nPrevious Therapies: \t\tReasons for Discontinuation:\t\tDuration of Therapy:\n________________\t\t_______________________\t            ________________\n________________\t\t_______________________\t\t________________\n________________\t\t_______________________\t\t________________\n\u000f\n\u003C\u003CPhysician’s Letterhead>>\n\u003C\u003CIf applicable, address body surface area: My patient has atopic dermatitis located on \u003C\u003Cinsert location on the body>> with a total body surface area of \u003C\u003Center % of the patient’s body surface area. Note that plans typically require a total body surface area of less than or equal to 20%>>.\nPlease contact me at \u003C\u003CXXX-XXX-XXXX>> for any additional information you may require regarding this appeal. I look forward to your timely approval.\nThank you for your attention to this matter.\nSincerely,\n_______________________________________\n\u003C\u003CPrescribing Physician ","cbCaik3PGANgJyCk","https://ap.wps.com/l/cbCaik3PGANgJyCk","docx",40991,6,"English","# Template Letter of Appeal for Atopic Dermatitis\n## Request and Patient Information\n## Clinical Rationale and Supporting History\n## Prior Therapies, Step-Through Requirements, and Body Surface Area\n## Contact, Signature, and Enclosures\n## Indication and Limitations of Use\n## Important Safety Information: Serious Infections","[{\"question\":\"What information must be included to appeal a prior authorization denial?\",\"answer\":\"The denial reason from the prior authorization denial letter must be directly addressed, along with patient details, diagnosis codes, case/request ID, and a clinical rationale supporting medical appropriateness for OPZELURA.\"},{\"question\":\"How should the prescriber address step-through requirements in the appeal?\",\"answer\":\"If applicable, the prescriber should confirm the patient met the plan’s step-through requirements or explain why step-through drugs are ineffective, contraindicated, or not tolerated. The template notes some plans may not require topical corticosteroids in sensitive areas.\"},{\"question\":\"What safety concerns are highlighted for OPZELURA in this template?\",\"answer\":\"Patients may be at risk for serious infections, including active tuberculosis and invasive fungal infections. The template advises avoiding use in patients with active serious infection, stopping treatment if serious infection develops, and monitoring for infection signs.\"}]","TEMPLATE LETTER OF APPEAL FOR ATOPIC DERMATITIS - Sample | DOCX"]